secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001140361-26-009115
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics projects $400-600M in F351 revenue within 5 years; provides Cullgen TRK degrader update
--------------------------------------------------------------------------------

- Company sees potential $400-600M revenue for Hydronidone (F351) in liver fibrosis within 5 years.
- Expects ETUARY for lung fibrosis to sustain ~$100M absent near-term generic competition.
- Sees 20-25% net margins for commercial products; favorable R&D tax deductibility in Beijing/Shanghai campuses.
- Cullgen's TRK degrader CG001419 Phase 2 pain trial enrolling at doses expected to show ~95% TRK degradation.
- Cullgen's degrader antibody conjugates (DAC) show ~10-100x potency vs standalone degrader in vitro/animal models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126009115/0001140361-26-009115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126009115/ef20067723_form8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-009115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer